Sofie (Sofie Biosciences Acquired Zevacor)

19 articles about Sofie (Sofie Biosciences Acquired Zevacor)

• Life Molecular Imaging and SOFIE announce Neuraceq® availability in Cleveland

  4/5/2024

  Life Molecular Imaging and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE's radiopharmaceutical manufacturing site located in Cleveland, Ohio.

• RLS and Sofie Enter Strategic Partnership for Distribution of Nuclear Medicine Doses for Patients

  6/21/2023

  RLS, Inc., the third-largest nuclear medicine pharmacy network in the US, and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, entered into a strategic partnership for RLS to distribute SOFIE nuclear medicine doses for patients.

• IND granted for FAP targeting therapeutic in SOFIE partnership

  1/17/2023

  SOFIE Biosciences, an established US manufacturer and developer of radiopharmaceuticals, will be supporting, through companion diagnostic [68Ga]FAPI-46 PET, Yantai LNC Biotechnology's recently FDA accepted clinical study.

• First Patient Imaged in SOFIE's FAPI Phase II trial

  10/13/2022

  SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [ 68 Ga]FAPI-46 at NYU Langone in its US Clinical Trial of Fibroblast Activation Protein Inhibitor (FAPI).

• SOFIE to Commercially Supply FDA-Approved PYLARIFY® (piflufolastat F 18) Injection

  5/28/2021

  SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, will be commercially manufacturing and distributing PYLARIFY® injection, an F 18-labeled prostate-specific membrane antigen targeted positron emission tomography imaging agent.

• SOFIE affiliate, iTheranostics, executes agreement for its promising library of Fibroblast Activation Protein (FAP) targeted theranostics

  3/30/2021

  Novartis has acquired global development and commercial rights to therapeutic applications for iTheranostics' library of FAP-targeted drugs licensed from University of Heidelberg

• SOFIE Breaks Ground On 30,000 Sq Ft Theranostic Center Of Excellence

  6/24/2019

  The acquired space is being used for the construction of a new Radiopharmaceutical Contract Manufacturing Center of Excellence

• SOFIE And University Clinic Heidelberg Sign License Agreement For Theranostics That Target Cancer Associated Fibroblasts

  6/21/2019

  SOFIE Inc. (SOFIE), a Theranostics company, is pleased to announce an exclusive global license with University Clinic Heidelberg (UKHD) for a class of molecular targeted diagnostics and radiotherapeutics ("theranostics") that are designed to identify and break down cancer associated fibroblasts in tumor stroma and irradiate nearby cancer cells.

• Acquisition Of Zevacor Pharma Complete, Rebranding As Sofie

  9/28/2017

• Sofie Biosciences To Acquire Zevacor Pharma

  5/12/2017

• Sofie Biosciences Oversubscribes An Investment Round

  6/14/2016

• PerkinElmer And Sofie Biosciences Extend And Expand Partnership

  6/13/2016

• Sofie Biosciences Receives $1.5M National Cancer Institute Phase 2 SBIR

  10/16/2014

• Sofie Biosciences Partners With PerkinElmer, Inc. To Deliver Benchtop PET In Vivo Imaging Systems To Preclinical Research Professionals

  6/13/2014

• In Vivo Imaging Company, Sofie Biosciences, Raises $5 Million Series A

  10/15/2013

• Sofie Biosciences Receives $1.8M Phase II SBIR Grant

  10/2/2013

• Sofie Biosciences Receives $1M Phase II SBIR Grant From the Department of Energy

  7/11/2012

• Sofie Biosciences Launches ELIXYS, A New Generation of Automated Radiochemistry for Producing PET Imaging Probes

  6/5/2012

• Sofie Biosciences is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology

  1/25/2012